Consolidation with (90)Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up
| Autor: | Alicja M. Gruszka, Katarzyna Krawczyk, Dagmara Zimowska-Curylo, Anna Staszczak, Wojciech Jurczak, Pier Luigi Zinzani, Tomasz Wróbel, Monika Długosz-Danecka, Elżbieta Kisiel, Michal Szymczyk, Alicja Hubalewska-Dydejczyk, Agnieszka Giza, Aleksander B. Skotnicki, Malgorzata Jakobczyk, Marta Szostek, Wanda Knopinska-Posluszny |
|---|---|
| Přispěvatelé: | Jurczak, Wojciech, Gruszka, Alicja M, Sowa Staszczak, Anna, Dlugosz-Danecka, Monika, Szostek, Marta, Zimowska-Curylo, Dagmara, Giza, Agnieszka, Krawczyk, Katarzyna, Jakobczyk, Malgorzata, Hubalewska-Dydejczyk, Alicja, Szymczyk, Michal, Wróbel, Tomasz, Knopińska-Posłuszny, Wanda, Kisiel, Elżbieta, Skotnicki, Aleksander, Zinzani, Pier Luigi |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Ibritumomab tiuxetan 03 medical and health sciences 0302 clinical medicine ibritumomab tiuxetan Internal medicine medicine 90Y ibritumomab tiuxetan Chemotherapy Mantle cell lymphoma business.industry Hematology medicine.disease Fludarabine Lymphoma High dose therapy 030220 oncology & carcinogenesis Radioimmunotherapy radioimmunotherapy business 030215 immunology medicine.drug |
| Popis: | Polish Lymphoma Research Group performed a phase-II trial to test whether (90)Y ibritumomab tiuxetan radioimmunotherapy (Y90) may constitute an alternative consolidation for mantle cell lymphoma patients unfit for high-dose therapy. Forty-six patients were consolidated with Y90 following response to the 1st (n = 34) or 2nd line (n = 12) (immuno)chemotherapy. Majority of the patients had advanced disease (stage IV and presence of B-symptoms in 85% and 70%, respectively) and high MIPI (5.8, range 4-7). Consolidation with Y90 increased the complete remission (CR) rate obtained by the 1st line therapy from 41% to 91% and allowed for median PFS of 3.3 and OS of 6.5 years. In the first relapse, CR rate increased from 16% to 75%, while median PFS and OS totaled 2.2 and 6.5 years, respectively. At 8 years, 30% of patients, consolidated in the 1st line CR were alive, without relapse. Toxicity associated with Y90 is manageable, more severe after fludarabine-based regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|